A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

The Washington University

Status and phase

Terminated

Phase 2

Conditions

Multiple Myeloma

Treatments

Drug: Granix

Drug: High dose melphalan (HDR)

Procedure: Autologous Stem Cell Transplant (ASCT)

Study type

Interventional

Funder types

Other

Identifiers

NCT02112045

201405057

Details and patient eligibility

About

This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma. Chemotherapy drugs, such as melphalan, are given to prepare the bone marrow for the stem cell transplant. Giving colony-stimulating factors, such as XMO2 Filgrastim (Granix), may help multiple myeloma cells move from the patient's bone marrow to the blood where they may be more sensitive to treatment with melphalan. It is not yet known whether adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant will work better than melphalan alone in treating multiple myeloma

Enrollment

90 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Symptomatic multiple myeloma requiring treatment
Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapy
At least 18 years of age
Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 × 10^6 CD34+ cells/kg based on patient body weight.
Adequate organ function as measured by:
- Cardiac function: Left ventricular ejection fraction at rest ≥40%
- Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine amino transferase (AST/ALT) ≤3 × ULN
- Renal function: Creatinine clearance ≥40 mL/minute (measured or calculated/estimated)
- Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory vital capacity (FVC) ≥50% of predicted value
- Oxygen saturation ≥92% on room air
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion criteria

Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to ASCT
Prior stem cell transplant (autologous or allogeneic)
Smoldering MM not requiring therapy
Plasma cell leukemia
Systemic amyloid light chain amyloidosis
Active bacterial, viral, or fungal infection
Seropositive for human immunodeficiency virus (HIV)
Known, active hepatitis A, B, or C Infection
Pregnant or breastfeeding.
Receiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on Day +100.
Hypersensitive or intolerant to any component of the study drug(s) formulation
Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor, etc) or undergoing apheresis < 14 days prior to the start of treatment on protocol (Day -7).